Jioyoung Expands Rare Drug Supply by 52% in Two Years
WellsBio Appoints Seo Seok-chan as New CEO
Medifoam® and BETAfoam®
[Provided by Samjin Pharmaceutical]
Samjin Pharmaceutical announced on the 3rd that it has established a collaborative sales system with the global healthcare company ‘Mundipharma’ for wound care dressing brands ‘Medifoam®’ and ‘BETAfoam®’. ‘Medifoam®’ is a moist dressing product based on polyurethane foam, while ‘BETAfoam®’ contains 3% PVP-I (povidone-iodine) and is covered by the same insurance rate as regular foam dressings. Samjin Pharmaceutical plans to quickly enter the dressing market targeting secondary hospitals. Especially, to create synergy using orthopedic networks, they plan to link ‘Medifoam®’ and ‘BETAfoam®’ with existing antibacterial and analgesic portfolios, including ‘Tauroline’ (antifungal) and ‘Synerjet’ (pain reliever), to comprehensively expand their solution range covering infection, pain, and wound care.
Jioyoung Cheonan Logistics Center
[Provided by Jioyoung]
On the 3rd, Jioyoung, the leading pharmaceutical distributor in the country, announced that it has expanded the number of items supplied from 80 in the first year of rare drug supply in 2023 to 122, marking a 52.2% increase over two years, based on its differentiated logistics capabilities. The supply of rare drugs surged by 87.2%, from 99,582 units in 2023 to 186,398 units last year. The supply also recorded 195,429 units in the recent year (October 2024 to September 2025), reflecting a 16.3% growth compared to the same period the previous year (168,077 units). Jioyoung Chairman Cho Sun-hye said, “Rare drug distribution is not merely logistics but an important task to expand treatment opportunities and improve survival chances for patients,” and emphasized fulfilling the company’s social responsibility as a part of the public pharmaceutical distribution network while further solidifying the trust-based supply system.
Seo Seok-chan, CEO of WellsBio
[Provided by the Pharmgen Science Group]
The Pharmgen Science Group announced on the 3rd that Seo Seok-chan, who was the Head of Strategic Investment Team at BeLight Investment and Head of the 1st Strategic Committee at Pharmgen Group, has been appointed as the new CEO of its affiliate WellsBio. Seo, who previously served as a director in WellsBio’s overseas sales, marketing, and planning coordination for about two years since 2021, is expected to lead the sustainable growth of the company. An alumnus of the Naval Academy and Ohio State University with an MBA, Seo has gained global business insights and capabilities by working at multinational companies such as Metanex and Qatar Energy (formerly Muntajat). He stated, “I will grow WellsBio into a stable and sustainable in vitro diagnostics specialized company through active communication with employees.” (Seoul = Yonhap News)